Xintang Li

Georgetown University — United States

Biochemistry, Genetics and Molecular Biology · Life Sciences

3h-index63citations35works3.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Histone Deacetylase Inhibitors Research(26), Peptidase Inhibition and Analysis(22), Cancer, Stress, Anesthesia, and Immune Response(14), Immune cells in cancer(8), Protein Degradation and Inhibitors(6)

Publications35 total

Abstract 2187: Functional classification of tumor-associated macrophages and changes in TAM subpopulations in response to various immunotherapies
Cancer Research·2025
Abstract 2253: HDAC6 inhibitors reprogram macrophages in antitumor-adoptive cell therapy
Cancer Research·2025
Abstract 2148: HDAC6 inhibitors modulate macrophage functional activity in the post-radiotherapy tumor microenvironment
Cancer Research·2025
Abstract 3144: Selective HDAC10 inhibitor enhances innate antitumor immunity
Cancer Research·2025
Abstract 6139: Changes in macrophage phenotype and function with aging affects tumor growth and tumor microenvironment in murine cancer models
Cancer Research·2025
Abstract 4216: Advancing cancer immunotherapy through the development of a novel selective HDAC6 inhibitors
Cancer Research·2025
Targeting prostate cancer by new bispecific monocyte engager directed to prostate-specific membrane antigen
PLoS ONE·2025· 1 citedOpen Access
Cell therapy using ex vivo reprogrammed macrophages enhances antitumor immune responses in melanoma
Journal of Experimental & Clinical Cancer Research·2024· 18 citedOpen Access
Abstract 4583: Development of selective HDAC6 inhibitors to improve cancer immunotherapy
Cancer Research·2024
Abstract 2688: Age-associated changes in macrophage function and phenotype affects cancer development, and the efficacy of macrophage targeted anticancer therapies in murine melanoma model
Cancer Research·2024
Abstract 1122: Inhibition of HDAC6 enhanced radiation therapy induced antitumor response in melanoma
Cancer Research·2024
Abstract 5247: Reprogramming tumor microenvironment with intratumor macrophage adoptive cell therapy in melanoma
Cancer Research·2024
Targeting HDAC6 improves anti-CD47 immunotherapy
Journal of Experimental & Clinical Cancer Research·2024· 21 citedOpen Access
Supplementary Figure 6 A_B from Radiotherapy-induced Immune Response Enhanced by Selective HDAC6 Inhibition
2023Open Access
Supplementary Figure 1 from Radiotherapy-induced Immune Response Enhanced by Selective HDAC6 Inhibition
2023Open Access
Supplementary Figure 6 A_B from Radiotherapy-induced Immune Response Enhanced by Selective HDAC6 Inhibition
2023Open Access
Supplementary Figure 2 from Radiotherapy-induced Immune Response Enhanced by Selective HDAC6 Inhibition
2023Open Access
Supplementary Figure 5 from Radiotherapy-induced Immune Response Enhanced by Selective HDAC6 Inhibition
2023Open Access
Data from Radiotherapy-induced Immune Response Enhanced by Selective HDAC6 Inhibition
2023Open Access
Supplementary Figure 5 from Radiotherapy-induced Immune Response Enhanced by Selective HDAC6 Inhibition
2023Open Access
page 1 of 2Next →

Frequent Co-authors

Satish Noonepalle(34), Alejandro Villagra(29), Anatoly Dritschilo(24), Nima Aghdam(22), Maria Gracia-Hernandez(21), Christian Zevallos‐Delgado(21), Scott Grindrod(21), Mira Jung(19), Manasa Suresh(12), Karen Tan(9), Nithya Gajendran(9), Alejandro Villagra(5), David Quiceno-Torres(5), Nithya Gajendran(4), Maho Shibata(4), Bryan Weselman(4), Duncan J. Wardrop(4), Karthik Musunuri(4), David Quiceno(4), Hawa Coulibaly(3)